Drugs / ABX-IL8
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00035828 | Dec 2001 → Dec 2002 | chronic bronchitis | Abgenix | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABX-IL8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00035828 ↗ |
| Action | Inhibit | “A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo” NCT00035828 ↗ |
| Modality | Monoclonal antibody | “Fully Human Anti-IL8 Monoclonal Antibody” NCT00035828 ↗ |
| Target | IL8 | “the highly specific antibody to IL-8 (such as ABX-IL8)” NCT00035828 ↗ |